94 results
8-K
KA
Kineta Inc
24 Apr 24
Entry into a Material Definitive Agreement
4:00pm
Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2
8-K
EX-10.1
KA
Kineta Inc
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
. Treasury Department (“OFAC”).
(kk)U.S. Real Property Holding Corporation. The Company is not and has never been a U.S. real property holding
424B5
KA
Kineta Inc
5 Oct 23
Prospectus supplement for primary offering
10:47am
disclosed, on June 27, 2023, we received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating … Qualifications Department of Nasdaq notifying the Company that, based on its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, the Company has
8-K
ixsx2dkgdyn1w3t
16 Aug 23
Other Events
4:00pm
8-K
u29ro3kqbcyl
3 Jul 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9:31am
8-K
EX-99.1
1arod mkfmaln0t0
11 May 23
Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update
5:20pm
8-K
EX-10.1
pdeiy3j2v4c tmkz
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
8-K
EX-99.6
ro3e9x
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.5
14xif xbrv
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-3.3
ierv49
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-10.15
clrp62p67 pb2fb
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
424B3
w1iku46v5r6bj5si dyt
10 Nov 22
Prospectus supplement
4:21pm